We are live on ! Find out more
BLFS icon

BioLife Solutions

80 hedge funds and large institutions have $168M invested in BioLife Solutions in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 16

0% more funds holding

Funds holding: 8080 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

0.32% less ownership

Funds ownership: 50.36%50.04% (-0.32%)

2% less capital invested

Capital invested by funds: $170M → $168M (-$2.87M)

59% less call options, than puts

Call options by funds: $179K | Put options by funds: $437K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
80
Holders Change
Holders Change %
0%
% of All Funds
1.58%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
42
Reduced
16
Closed
10
Calls
$179K
Puts
$437K
Net Calls
-$258K
Net Calls Change
+$183K
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$39.9M +$650K +40,000 +2%
PWAM
2
Park West Asset Management
California
$14.1M +$1.32M +81,145 +10%
Vanguard Group
3
Vanguard Group
Pennsylvania
$10.1M +$32.4K +1,992 +0.3%
Ameriprise
4
Ameriprise
Minnesota
$9.72M +$850K +52,277 +10%
SCM
5
Sandler Capital Management
New York
$9.19M -$975K -60,000 -10%
BlackRock
6
BlackRock
New York
$8.99M +$48.7K +2,998 +0.5%
Russell Investments Group
7
Russell Investments Group
United Kingdom
$8.99M -$444K -27,304 -5%
DCM
8
Driehaus Capital Management
Illinois
$7.71M -$413K -25,410 -5%
RIM
9
Ranger Investment Management
Texas
$4.86M -$126K -7,739 -3%
GIM
10
Granahan Investment Management
Massachusetts
$4.49M +$122K +7,478 +3%
GC
11
GMT Capital
Georgia
$4.11M -$32.5K -2,000 -0.8%
RA
12
Royce & Associates
New York
$3.57M +$391K +24,061 +12%
EIM
13
Essex Investment Management
Massachusetts
$3.43M +$162K +9,943 +5%
PHP
14
Parkman Healthcare Partners
Connecticut
$2.69M +$2.7M +166,000 New
TAM
15
THB Asset Management
Connecticut
$2.52M +$137K +8,452 +6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.27M +$80K +4,922 +4%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$2.27M +$197K +12,100 +9%
RC
18
Roubaix Capital
Colorado
$2.24M +$952K +58,584 +73%
State Street
19
State Street
Massachusetts
$2.22M +$114K +7,001 +5%
Northern Trust
20
Northern Trust
Illinois
$2.09M +$374K +23,001 +22%
Allianz Asset Management
21
Allianz Asset Management
Germany
$1.49M +$74.8K +4,600 +5%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.47M +$198K +12,198 +16%
Millennium Management
23
Millennium Management
New York
$1.43M +$456K +28,065 +46%
PCM
24
Perkins Capital Management
Minnesota
$1.32M -$483K -29,700 -27%
CS
25
Candriam SCA
Luxembourg
$1.23M

BLFS Hedge Fund Activity: Q4 2019 in Review

80 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q4 2019, worth a combined $168M — down 1.7% from $170M a quarter earlier.

Fund positioning in BLFS was balanced in Q4 2019: 10 funds opened new positions, 10 closed out, 42 added to existing stakes and 16 trimmed.

The largest buyer was Park West Asset Management, adding an estimated $1.32M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.49M sold.

  • 80 institutional investors held BioLife Solutions (BLFS) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $168M of BioLife Solutions stock for Q4 2019, down 1.7% quarter-over-quarter.
  • 10 funds opened new BioLife Solutions positions in Q4 2019 and 10 closed out, a net change of 0 holders.
  • The largest BioLife Solutions buyer in Q4 2019 was Park West Asset Management, an estimated $1.32M added.
  • The largest BioLife Solutions seller in Q4 2019 was Fidelity Investments, an estimated $2.49M sold.

Based on aggregated 13F filings for Q4 2019.